Our results were in line with the findings in Japanese breast cancer patients receiving a standard AC regimen (doxorubicin and cyclophosphamide) that grade 4 neutropenia hardly developed in CYP2B6*6 carriers55. This evidence concerns the gene CYP2B6 and breast carcinoma.